Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations

Xenobiotica

Volumn 36, Issue 12, 2006, Pages 1201-1209

  Yamazaki, H ^a   Okayama, A ^a   Imai, N ^a   Guengerich, F P ^b   Shimizu, M ^a  

^a SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Astemizole; CYP2J2; CYP2J2*7; Ebastine; Inter individual P450 variation; Total P450

Indexed keywords

ASTEMIZOLE; CYTOCHROME P450; CYTOCHROME P450 2J2; EBASTINE;

ALLELE; ARTICLE; CATALYSIS; CAUCASIAN; CONTROLLED STUDY; DEMETHYLATION; DNA SEQUENCE; DRUG DISPOSITION; DRUG HYDROXYLATION; ENZYME ACTIVITY; ETHNIC DIFFERENCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; JAPANESE; LIVER MICROSOME; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 ENZYME SYSTEM; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE EXPRESSION; GENOTYPE; HUMANS; JAPAN; MALE; MICROSOMES, LIVER; MIDDLE AGED; OXIDATION-REDUCTION; OXYGENASES; XENOBIOTICS;

EID: 33845712373     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250600944318     Document Type: Article

References (27)

1. Bjornsson TD, Wagner JA, Donahue SR, Harper D, Karim A, Khouri MS, Murphy WR, Roman K, Schneck D, Sonnichsen DS, et al. 2003. A review and assessment of potential sources of ethnic differences in drug responsiveness. Journal of Clinical Pharmacology 43:943-967.
2. Guengerich FP. 2005. Human cytochrome P450 enzymes. In: Ortiz de Montellano PR, editor. Cytochrome P450: Structure, mechanism, and biochemistry, 3rd ed. New York, NY: Kluwer Academic/Plenum. pp. 377-530.
3. Hashizume T, Imaoka S, Mise M, Terauchi Y, Fujii T, Miyazaki H, Kamataki T, Funae Y. 2002. Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. Journal of Pharmacology and Experimental Therapeutics 300:298-304.
4. Hashizume T, Mise M, Terauchi Y, O L, Fujii T, Miyazaki H, Inaba T. 1998. N-dealkylation and hydroxylation of ebastine by human liver cytochrome P450. Drug Metabolism and Disposition 26:566-571.
5. Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP, Shimada T. 1997. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 7:103-113.
6. Inoue S, Howgate EM, Rowland-Yao K, Shimada T, Yamazaki H, Tucker GT, Rostami-Hodjegan A. 2006. Prediction of in vivo drug clearance from in vitro data. II: Potential inter-ethnic differences. Xenobiotica 36:499-513.
7. King LM, Gainer JV, David GL, Dai D, Goldstein JA, Browne NJ, Zelden DC. 2005. Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharmacogenetics and Genomics 15:7-13.
8. King LM, Ma JX, Srettabunjong S, Graves J, Bradbury JA, Li LP, Spiecker M, Liao JK, Mohrenweiser H, Zeldin DC. 2002. Cloning of CYP2J2 gene and identification of functional polymorphisms. Molecular Pharmacology 61:840-852.
9. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
10. Lee SS, Jeong H-E, Liu K-H, Ryu J-Y, Moon T, Yoon CN, Oh SJ, Yun C-H, Shin J-G. 2005. Identification and functional characterization of novel CYP2J2 variants: G312R variant causes loss of enzyme catalytic activity. Pharmacogenetics and Genomics 15:105-113.
11. Lin YS, Dowling ALS, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, Thummel KE. 2002. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Molecular Pharmacology 62:162-172.
12. Matsumoto S, Hirama T, Kim HJ, Nagata K, Yamazoe Y. 2003. In vitro inhibition of human small intestinal and liver microsomal astemizole O-demethylation: Different contribution of CYP2J2 in the small intestine and liver. Xenobiotica 33:615-623.
13. Matsumoto S, Hirama T, Matsubara T, Nagata K, Yamazoe Y. 2002. Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. Drug Metabolism and Disposition 30:1240-1245.
14. Nelson DR, Zeldin DC, Hoffman SMG, Maltais LJ, Wain HM, Nebert DW. 2004. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14:1-18.
15. Omura T, Sato R. 1964. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. Journal of Biological Chemistry 239:2370-2378.
16. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. 2006. The human intestinal cytochrome P450 'pie'. Drug Metabolism and Disposition 34:880-886.
17. Parikh A, Gillam EMJ, Guengerich FP. 1997. Drug metabolism by Escherichia coli expressing human cytochromes P450. Nature Biotechnology 15:784-788.
18. Rendic S. 2002. Summary of information on human CYP enzymes: Human P450 metabolism data. Drug Metabolism Reviews 34:83-448.
19. Scarborough PE, Ma J, Qu W, Zeldin DC. 1999. P450 subfamily CYP2J and their roles in the bioactivation of arachidonic acid in extrahepatic tissues. Drug Metabolism Reviews 31:205-234.
20. Shimada T, Tsumura F, Yamazaki H. 1999. Prediction of human microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone using kinetic parameters of recombinant cytochrome P450 enzymes. Drug Metabolism and Disposition 27:1274-1280.
21. Shimada T, Tsumura F, Yamazaki H, Guengerich FP, Inoue K. 2001. Characterization of (±)-bufuralol 1′-hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6 gene. Pharmacogenetics 11:143-156.
22. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics 270:414-423.
23. Spiecker M, Darius H, Hankeln T, Soufi M, Sattler AM, Schaefer JR, Node K, Borgel J, Mugge A, Lindpaintner K, et al. 2004. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 110:2132-2136.
24. Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC. 1996. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachisonic acid epoxygenase highly expressed in heart. Journal of Biological Chemistry 271:3460-3468.
25. Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Honda G, Nakagawa K, Ishizaki T, Kamataki T. 2004. CYP3A5 contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects. Drug Metabolism and Pharmacokinetics 19:120-129.
26. Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Saito T, Parkinson A, Nakagawa K, Kamataki T. 2005. Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: Lack of co-regulation of the expression of CYP3A in Japanese livers. Xenobiotica 35:69-83.
27. Yamazaki H, Nakano M, Imai Y, Ueng Y-F, Guengerich FP, Shimada T. 1996. Roles of cytochrome b5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes. Archives of Biochemistry and Biophysics 325:174-182.